145 related articles for article (PubMed ID: 32590508)
1. β-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: are risks related to individual product safety profile?
Smith DM; Coop CA; Freeman TM
Curr Opin Allergy Clin Immunol; 2020 Aug; 20(4):401-406. PubMed ID: 32590508
[TBL] [Abstract][Full Text] [Related]
2. Are ACE Inhibitors and Beta-blockers Dangerous in Patients at Risk for Anaphylaxis?
Coop CA; Schapira RS; Freeman TM
J Allergy Clin Immunol Pract; 2017; 5(5):1207-1211. PubMed ID: 28552379
[TBL] [Abstract][Full Text] [Related]
3. The safety of sublingual immunotherapy, can the rare systemic reactions be prevented?
Cavaliere C; Incorvaia C; Begvarfaj E; Orlando MP; Turchetta R; Musacchio A; Ralli M; Ciofalo A; Greco A; de Vincentiis M; Masieri S
Expert Opin Drug Saf; 2021 Mar; 20(3):259-264. PubMed ID: 33427529
[No Abstract] [Full Text] [Related]
4. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets.
Nolte H; Casale TB; Lockey RF; Fogh BS; Kaur A; Lu S; Nelson HS
J Allergy Clin Immunol Pract; 2017; 5(1):84-89.e3. PubMed ID: 27838323
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of Sublingual Immunotherapy Tablets and Management of Potential Adverse Effects: Austrian, German, and Swiss Expert Recommendations.
Sturm GJ; Vogelberg C; Marchon M; Horn A; Vitzthum HG; Memar-Baschi MP; Kleine-Tebbe J
Clin Ther; 2019 Sep; 41(9):1880-1888. PubMed ID: 31353131
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase.
Stoevesandt J; Hain J; Stolze I; Kerstan A; Trautmann A
Clin Exp Allergy; 2014; 44(5):747-55. PubMed ID: 24447144
[TBL] [Abstract][Full Text] [Related]
7. Clinical aspects of sublingual immunotherapy tablets and drops.
Tankersley M; Han JK; Nolte H
Ann Allergy Asthma Immunol; 2020 Jun; 124(6):573-582. PubMed ID: 31923544
[TBL] [Abstract][Full Text] [Related]
8. Local Side Effects of Sublingual and Oral Immunotherapy.
Passalacqua G; Nowak-Węgrzyn A; Canonica GW
J Allergy Clin Immunol Pract; 2017; 5(1):13-21. PubMed ID: 27527548
[TBL] [Abstract][Full Text] [Related]
9. Risk for Anaphylactic Reaction from Cardiac Catheterization in Patients Receiving β-Adrenergic Blockers or Angiotensin-Converting Enzyme-Inhibitors.
Smith MA; Newton LP; Barcena Blanch MA; Cuervo-Pardo L; Cho L; Newton D; Wang X; Li M; Lang DM
J Allergy Clin Immunol Pract; 2020 Jun; 8(6):1900-1905. PubMed ID: 31683029
[TBL] [Abstract][Full Text] [Related]
10. Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association.
Gagne JJ; Han X; Hennessy S; Leonard CE; Chrischilles EA; Carnahan RM; Wang SV; Fuller C; Iyer A; Katcoff H; Woodworth TS; Archdeacon P; Meyer TE; Schneeweiss S; Toh S
Clin Pharmacol Ther; 2016 Nov; 100(5):558-564. PubMed ID: 27416001
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy in immunotherapy-associated systemic reactions.
Carlson GS; Wong PH; White KM; Quinn JM
J Allergy Clin Immunol Pract; 2017; 5(5):1430-1432. PubMed ID: 28694048
[No Abstract] [Full Text] [Related]
12. Sublingual grass and ragweed immunotherapy: Clinical considerations-a PRACTALL consensus report.
Li JT; Bernstein DI; Calderon MA; Casale TB; Cox L; Passalacqua G; Pfaar O; Papadopoulos NG
J Allergy Clin Immunol; 2016 Feb; 137(2):369-76. PubMed ID: 26371843
[TBL] [Abstract][Full Text] [Related]
13. Current Evidence on Safety and Practical Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United States.
Epstein TG; Calabria C; Cox LS; Dreborg S
J Allergy Clin Immunol Pract; 2017; 5(1):34-40.e2. PubMed ID: 27815065
[TBL] [Abstract][Full Text] [Related]
14. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
[TBL] [Abstract][Full Text] [Related]
15. A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice.
Bernstein DI; Bardelas JA; Svanholm Fogh B; Kaur A; Li Z; Nolte H
Postgrad Med; 2017 Aug; 129(6):590-597. PubMed ID: 28326906
[TBL] [Abstract][Full Text] [Related]
16. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming.
Nassiri M; Babina M; Dölle S; Edenharter G; Ruëff F; Worm M
J Allergy Clin Immunol; 2015 Feb; 135(2):491-9. PubMed ID: 25441633
[TBL] [Abstract][Full Text] [Related]
17. Safety of sublingual immunotherapy in children.
Frati F; Ridolo E; Fuiano N; Barberi S; Dell'Albani I; Landi M; Ricciardi L; Scala G; Incorvaia C
Expert Opin Drug Saf; 2014 Jul; 13(7):947-53. PubMed ID: 24821477
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis.
Lee S; Hess EP; Nestler DM; Bellamkonda Athmaram VR; Bellolio MF; Decker WW; Li JT; Hagan JB; Manivannan V; Vukov SC; Campbell RL
J Allergy Clin Immunol; 2013 Apr; 131(4):1103-8. PubMed ID: 23453138
[TBL] [Abstract][Full Text] [Related]
19. The safety of carbamylated monomeric allergoids for sublingual immunotherapy. Data from a pharmacovigilance study.
Compalati E; Incorvaia C; Urbano S; Strada P; Frati F
Immunotherapy; 2020 Feb; 12(3):195-202. PubMed ID: 31969034
[No Abstract] [Full Text] [Related]
20. Safety of Angiotensin-converting enzyme inhibitors in patients with insect venom allergies.
Stumpf JL; Shehab N; Patel AC
Ann Pharmacother; 2006 Apr; 40(4):699-703. PubMed ID: 16569814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
